drugset / Trial / NCT01012934
Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)
RandomizedCrossoverOpen-label
Summary
The objective of this study is to investigate the bioequivalence of Mylan's alendronate sodium 70 mg tablets to Merck's Fosamax 70 mg tablets following a single, oral 70 mg (1 x 70 mg) dose administration under fasting conditions.
Timeline
- Start
- 2002-07
- Primary completion
- 2002-08
- Completion
- 2002-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | 70 mg | Oral |
Indications
No indication recorded.